Last week, Senator Claire McCaskill, D-Missouri, together with the minority staff of the Senate Homeland Security and Government Affairs Committee (HSGAC), released a report on prescription drug price increases that affect the 20 products most commonly prescribed to seniors.
Last week, Senator Claire McCaskill, D-Missouri, together with the minority staff of the Senate Homeland Security and Government Affairs Committee (HSGAC), released a report on prescription drug price increases that affect the 20 products most commonly prescribed to seniors.
According to the report, which used data from CMS and the IQVIA National Sales Perspectives information service, prices increased over the last 5 years for all 20 drugs in question, which include the diabetes medications insulin glargine (Lantus) and insulin aspart (NovoLog).
On average, prices for these drugs increased by 12% every year for the past 5 years, a rate that is approximately 10 times higher than the average annual rate of inflation. The percent change in price between 2012 and 2017 ranged from a low of 31% (for the shingles vaccine Zostavax) to a high of 477% (for the brand-name nitroglycerin, Nitrostat).
According to the report, these continual increases in price are keeping healthcare costs high despite reduced use of many of these drugs; while prescriptions rose for treatments including the blood-thinner rivaroxaban (Xarelto) and the dry-eye drug cyclosporine (Restasis), many of the 20 most-prescribed drugs saw sharp declines in prescribing from 2012 to 2017; prescriptions for rosuvastatin (Crestor) dropped by 94%, and nitroglycerine by 93%, for example.
“These findings underscore the need for further investigation by the Committee and other policymakers into dramatic price spikes and their impact on healthcare system costs and financial burdens for the growing US senior population,” conclude the authors.
In a statement, McCaskill added, “Can you imagine if you went to an auto dealership and last year’s exact model was being sold at a [20%] mark-up, and then you went back the next year and it had happened again? That’s exactly what’s happening in the prescription drug industry, where the cost of identical drugs skyrockets year after year.”
Juliet Johnson, a representative of the Pharmaceutical Research and Manufacturers of America (PhRMA) told CNN that the document is “yet another misleading report that ignores the robust negotiation that occurs between Medicare Part D plans, middlemen and biopharmaceutical companies.” Johnson added that PhRMA agrees that “…more can be done to make Part D more affordable and predictable for seniors. One way to do that is to ensure seniors benefit from the significant negotiated savings when they pick up their medicine at the pharmacy.”
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.